Send page
    20 Sep 2011

    Wistrand advises Bluefish Pharmaceuticals

    Pharmaceutical company Bluefish Pharmaceuticals AB has acquired BMM Pharma AB, a subsidiary of BioPhausia AB.


    The portfolio acquired includes 19 pharmaceutical products, of which most are used in pain, inflammation and gastrointestinal therapy. Following the acquisition, Bluefish now has 68 products in its portfolio, of which 41 have already been launched.


    The acquisition is expected to increase net sales by approximately SEK 30 million. No personnel are included in the acquisition. The acquisition will be financed by means of a bridging loan from Färna Invest AB, which has also entered into an agreement for a new share issue.


    Bluefish Pharmaceuticals was founded in 2005 and focuses on the development, manufacture and sale of generic pharmaceuticals.

    Wistrand advised Bluefish in the acquisition, primarily through partners Lars hasp and Magnus Forssman.


    For further information:
    Magnus Forssman, partner Wistrand
    Direct: +46 8 50 72 0069
    Mobile: +46 709 50 72 69


    05 Dec 2017
    Wistrand assists Tacton Systems in conne...
    27 Nov 2017
    Wistrand appoints new partners
    25 Oct 2017
    Erik Ullberg and Gunilla Karlsson in GAL...
    09 Oct 2017
    Wistrand shortlisted for Sweden M&A Lega...
    20 Sep 2017
    Wistrand advises SBB on the acquisition ...
    15 Jun 2017
    Erik Ullberg in the book Sweepstakes & C...
    01 Jun 2017
    Wistrand advises SBB on the acquisition ...
    29 May 2017
    Labour Court rules on compensation for d...
    22 May 2017
    Erik Ullberg in GALA Gazette
    15 May 2017
    Wistrand advises in connection with the ...
    08 May 2017
    Wistrand advises Strawberry Properties o...
    28 Apr 2017
    Legal 500’s rankings for 2017 – Wistrand...